PH
PHVS.US Pharvaris BV
- Market cap
- USD 2.36B
- P/E
- -
- P/B
- 8.04x
- ROE
- -68.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PHVS.US undervalued?
Graham numberThe Graham number of Pharvaris BV cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharvaris BV fundamental analysis
No fundamental analysis for Pharvaris BV yet.
Pharvaris BV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase…
Full company profilePharvaris BV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharvaris BV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -614.47 | -8.44K | -80.5K | -150K | -252K | - | - | - |
| Operating Income | -4.31M | -8.97M | -28.5M | -54.1M | -86.7M | -96.9M | -146M | -170M | -194M |
| EBITDA | -4.31M | -8.98M | -29.7M | -42.3M | -86.6M | -99.6M | -145M | -173M | -187M |
| Net Income | -4.31M | -8.98M | -29.6M | -42.7M | -76.3M | -101M | -134M | -176M | -180M |
| EPS | -0.14 | -0.28 | -0.97 | -1.41 | -2.27 | -2.63 | -2.48 | -2.97 | -2.56 |
| Balance Sheet | |||||||||
| Total Assets | 5.43M | 20.6M | 101M | 212M | 168M | 399M | 291M | 301M | 295M |
| Total Liabilities | 481K | 1.92M | 5.31M | 7.14M | 18.5M | 14.6M | 23.6M | 30.2M | 30.1M |
| Shareholders' Equity | 4.95M | 18.7M | 95.8M | 205M | 149M | 384M | 268M | 271M | 265M |
| Cash & Short-term Investments | 5.39M | 20.3M | 98.6M | 209M | 162M | 391M | 281M | 292M | 283M |
| Total Debt | - | - | - | 250K | 437K | 239K | 861K | 777K | 604K |
| Cash Flow | |||||||||
| Operating Cash Flow | -3.92M | -6.68M | -21.5M | -44.6M | -67.2M | -93.0M | -120M | -137M | -173M |
| Capital Expenditure | 13.5K | 13.5K | 43.0K | 130K | 124K | 90.0K | 538K | 165K | 106K |
| Free Cash Flow | -3.93M | -6.69M | -21.5M | -44.7M | -67.3M | -93.1M | -121M | -137M | -173M |
| Ratios | |||||||||
| ROE | -87.1% | -48.1% | -30.9% | -20.8% | -51.1% | -26.3% | -50.1% | -64.8% | -68.0% |
| ROA | -79.4% | -43.6% | -29.3% | -20.1% | -45.5% | -25.3% | -46.1% | -58.3% | -61.0% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pharvaris BV dividends
Pharvaris BV has not paid dividends in the last 8 fiscal years.
Who owns Pharvaris BV
- Insiders 6.30%
- Institutions 93.70%
- Public & others 0.00%
- Shares outstanding 70.8M
- Free float 44.1M
Top funds holding PHVS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Health Care Inv | 3.39M | 4.78% | 0.00% | Sep 2026 |
| Polar Capital Healthcare Opports Inc | 1.92M | 2.71% | +31.67% | Sep 2026 |
| Fidelity Growth Company Fund | 1.37M | 1.94% | 0.00% | Aug 2026 |
| Fidelity Select Health Care | 800K | 1.13% | 0.00% | Aug 2026 |
| Polar Capital Biotech S Inc | 762K | 1.08% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth | 645K | 0.91% | 0.00% | Aug 2026 |
| T. Rowe Price Health Sciences | 439K | 0.62% | +55.73% | Sep 2026 |
| Fidelity Advisor Health Care I | 400K | 0.57% | 0.00% | Sep 2026 |
| Fidelity Growth Company K6 | 399K | 0.56% | 0.00% | Aug 2026 |
| MEDICAL BioHealth EUR Acc | 331K | 0.47% | +65.87% | Aug 2026 |
| Fidelity Small Cap Growth K6 | 326K | 0.46% | 0.00% | Aug 2026 |
| Fidelity Series Growth Company | 322K | 0.46% | -3.30% | Aug 2026 |
| iShares Biotechnology ETF | 258K | 0.36% | -0.19% | Oct 2026 |
| BNP Paribas US Small Cap ClassicC | 191K | 0.27% | +22.60% | Sep 2026 |
| BNP Paribas Health Cr Innovtr Cl Cap | 185K | 0.26% | +39.47% | Sep 2026 |
| Wellington Global Hlthcr Eq USD G Ac | 180K | 0.25% | -3.20% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 164K | 0.23% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 148K | 0.21% | 0.00% | Aug 2026 |
| iShares Core MSCI EAFE ETF | 130K | 0.18% | 0.00% | Oct 2026 |
| Fidelity Advisor Biotechnology I | 128K | 0.18% | 0.00% | Sep 2026 |
Top institutions holding PHVS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 6.57M | 9.27% | +4.47% | Jun 2026 |
| General Atlantic Llc | 6.55M | 9.25% | -18.43% | Jun 2026 |
| Foresite Capital Management IV, LLC | 4.78M | 6.75% | 0.00% | Jun 2026 |
| venBio Partners LLC | 4.64M | 6.56% | +0.09% | Jun 2026 |
| Viking Global Investors LP | 3.65M | 5.16% | 0.00% | Jun 2026 |
| EQT Fund Management S.à r.l. | 3.42M | 4.84% | 0.00% | Sep 2026 |
| Deerfield Management Co | 3.38M | 4.77% | +8.00% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 2.68M | 3.78% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 2.39M | 3.38% | +12.93% | Jun 2026 |
| Polar Capital Holdings PLC | 2.33M | 3.29% | +197.87% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.64M | 2.32% | +62.98% | Jun 2026 |
| COMMODORE CAPITAL LP | 1.43M | 2.01% | -25.74% | Jun 2026 |
| Novo A/S | 1.40M | 1.98% | -20.00% | Jun 2026 |
| Saturn V Capital Management LLC | 1.31M | 1.86% | +9.38% | Jun 2026 |
| TCG Crossover Management, LLC | 1.01M | 1.42% | 0.00% | Jun 2026 |
| Sofinnova Ventures | 881K | 1.24% | +7.70% | Jun 2026 |
| Patient Square Capital LP | 809K | 1.14% | +20.48% | Sep 2026 |
| 5AM Venture Management, LLC | 798K | 1.13% | 0.00% | Jun 2026 |
| Seven Fleet Capital Management LP | 775K | 1.09% | +144.56% | Jun 2026 |
| BlackRock Inc | 771K | 1.09% | +1.88% | Jun 2026 |
Pharvaris BV company profile
- Company name
- Pharvaris BV
- Ticker
- PHVS.US
- ISIN
- NL00150005Y4
- Exchange
- USA Stocks
- Listed since
- Feb 5, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 148
- Fiscal year end
- December
- Address
- Grafenauweg 8, Zug, Switzerland, 6300
- Phone
- 31 712036410
- Website
- pharvaris.com
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Pharvaris BV management
10- Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, CEO & Executive Director · born 1959
- Dr. Peng Lu M.D., Ph.D.President · born 1978
- Mr. David W. Nassif J.D.CFO, Chief Legal Officer & Corporate Secretary · born 1954
- Ms. Anna Nijdam M.Sc., R.A.Head of Strategic Finance & Principal Accounting Officer · born 1981
- Dr. Stefan Abele Ph.D.Chief Technology Operations Officer · born 1970
- Ms. Annick DeschoolmeesterChief Human Resources Officer · born 1973
- Dr. Anne A. Lesage Ph.D.Chief Early Development Officer · born 1961
- Mr. Wim Souverijns Ph.D.Chief Commercial Officer · born 1971
- Maggie BellerVP & Head of Corporate and Investor Communications
- Maryann CiminoDirector of Corporate Relations